The management of patient with osteoporosis in clinical practice

Authors

  • Luca Degli Esposti CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna - Italy
  • Elisa Giacomini CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna - Italy
  • Alessandro Ghigi CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna - Italy
  • Valentina Perrone CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna - Italy

DOI:

https://doi.org/10.33393/ao.2021.2198

Keywords:

Adherence to therapies, Administrative databases, Osteoporosis, Therapeutic appropriateness

Abstract

Osteoporosis is a systemic skeletal disorder characterized by increased bone fragility, which is associated with an enhanced fracture risk. The first fracture often represents indeed the clinical manifestation of this condition. In the present document we provided an overview of the economic and clinical impact of a not-adequate therapeutic appropriateness and suboptimal adherence to osteoporosis therapy, that are both widely reported in literature despite osteoporotic treatments have proved their efficacy in reducing fracture risk. Adequate treatment and adherence were reported to be associated with a lower risk of re-fracture and all-cause mortality. Moreover, healthcare costs in osteoporotic patients with previous fractures were significantly lower in those receiving osteoporosis treatment rather than among untreated patients. Nevertheless, these two key-factors are not improving over time. The measurement of indicators of adherence and therapeutic appropriateness allows to analyse the utilization profile of the drugs indicated for the treatment of osteoporosis and to evaluate the presence of possible deviation between the prescriptive behaviours observed in clinical practice and the recommendations reported in the guidelines. The periodic monitoring of such indicators together with prescribing audit activity could represent a useful tool for the optimization of osteoporosis management and to achieve a correct resource allocation. (Rheumatology)

References

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795. https://doi.org/10.1001/jama.285.6.785 PMID:11176917

Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, Sessa G. Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature. Front Pharmacol. 2017;8:803. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682013/. https://doi.org/10.3389/fphar.2017.00803 PMID:29163183

Figliomeni A, Signorini V, Mazzantini M. One year in review 2018: progress in osteoporosis treatment. Clin Exp Rheumatol. 2018;36(6):948-958. PMID:30526765

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733. https://doi.org/10.1007/s00198-006-0172-4 PMID:16983459

Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 2016;68(1):1-39. https://doi.org/10.4081/reumatismo.2016.870 PMID:27339372

Ricciardi A, Geraci A, Montagner IM, Alongi GD, Marinato L, Corso L. The role of osteoporosis in hip fractures in two Italian hospitals. SM J Orthop. 2016;2(4):1045. https://doi.org/10.36876/smjo.1045

Mafi Golchin M, Heidari L, Ghaderian SMH, Akhavan-Niaki H. Osteoporosis: A Silent Disease with Complex Genetic Contribution. J Genet Genomics. 2016;43(2):49-61. https://doi.org/10.1016/j.jgg.2015.12.001 PMID:26924688

Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1-2):136. https://doi.org/10.1007/s11657-013-0136-1 PMID:24113837

Degli Esposti L, Adami S, Iolascon G, et al. Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study. FE. 2011;12(3):99-105. https://doi.org/10.7175/fe.v12i3.125

IOF. Ossa Spezzate, Vite Spezzate: Un Piano d’azione per Superare l’emergenza Delle Fratture Da Fragilità in Italia. 2018. (Accessed September, 2020). Available from http://share.iofbonehealth.org/EU-6-Material/Reports/IOF%20Report_ITALY_DIGITAL_IT.pdf

Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871-1880. https://doi.org/10.1210/jc.2011-3060 PMID:22466336

Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int. 2013;24(1):209-217. https://doi.org/10.1007/s00198-012-2068-9 PMID:22832638

Keshishian A, Boytsov N, Burge R, et al. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int. 2017;28(8):2485-2494. https://doi.org/10.1007/s00198-017-4072-6 PMID:28536737

Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries. Arch Osteoporos. 2016;11(1):31. https://doi.org/10.1007/s11657-016-0285-0 PMID:27696099

Degli Esposti L, Girardi A, Saragoni S, et al; on the behalf of the Study group. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine. 2019;64(2):367-377. https://doi.org/10.1007/s12020-018-1824-9 PMID:30515678

Osteoporosi: esiti e costi della ridotta appropriatezza|Sanità24 - Il Sole 24 Ore [Internet]. [cited 2020 Jan 30]. (Accessed September, 2020). Available from: https://www.sanita24.ilsole24ore.com/art/medicina-e-ricerca/2019-07-18/osteoporosi-esiti-e-costi-ridotta-appropriatezza-164455.php?uuid=ACiUsfZ

Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435-1441. https://doi.org/10.1359/jbmr.080418 PMID:18442318

Tafaro L, Nati G, Leoni E, et al. Adherence to anti-osteoporotic therapies: role and determinants of “spot therapy”. Osteoporos Int. 2013;24(8):2319-2323. https://doi.org/10.1007/s00198-013-2283-z PMID:23404614

Greco EA, Migliaccio S, Marcocci C, Romagnoli E. Appropriatezza terapeutica in osteoporosi. L’Endocrinologo. 2017;18(4):153-158. https://doi.org/10.1007/s40619-017-0328-9

Nota 79. Gazzetta Ufficiale della Repubblica Italiana. Serie generale - n. 75. 30 Marzo 2017. [Internet]. [cited 2020 Jan 30]. (Accessed September, 2020). Available from: https://www.gazzettaufficiale.it/eli/id/2017/03/30/17A02253/sg

Quaderni del Ministero della Salute 4 - “Appropriatezza diagnostica e terapeutica nella prevenzione delle fratture da fragilità da osteoporosi”. [Internet]. (Accessed September, 2020). Available from: http://www.quadernidellasalute.it/imgs/C_17_pubblicazioni_1701_allegato.pdf

Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale 2015. Roma: Agenzia Italiana del Farmaco; 2016. (Accessed September, 2020). Available from https://www.aifa.gov.it/-/l-uso-dei-farmaci-in-italia-rapporto-osmed-20-6

Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale 2018. Roma: Agenzia Italiana del Farmaco; 2019. (Accessed September, 2020). Available from: https://www.aifa.gov.it/-/rapporto-osmed-20-1

Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr Rev. 2019;40(4):1109-1151. https://doi.org/10.1210/er.2018-00126 PMID:30321335

Giustina A, Adler RA, Binkley N, et al. Controversies in Vitamin D: Summary Statement From an International Conference. J Clin Endocrinol Metab. 2019;104(2):234-240. https://doi.org/10.1210/jc.2018-01414 PMID:30383226

Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20(2):239-244. https://doi.org/10.1007/s00198-008-0650-y PMID:18551242

Degli Esposti L, Saragoni S, Perrone V, et al. Economic burden of osteoporotic patients with fracture: effect of treatment with or without calcium/vitamin D supplements. NDS. 2020;12:21-30. https://doi.org/10.2147/NDS.S234911

Hiligsmann M, Evers SM, Ben Sedrine W, et al. A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics. 2015;33(3):205-224. https://doi.org/10.1007/s40273-014-0231-1 PMID:25377850

Perrone V, Ghigi A, Nappi C, et al. Esiti clinici e sostenibilità economica nel trattamento delle fratture da fragilità ossea. Il Progetto FASTER (Fractures: algorithm for the suSTainability and the Effectiveness of caRe). Giornale Italiano di Farmacia Clinica. 2020;34(3):114-122. https://doi.org/10.1721/3442.34309

Baronciani D, Perrone E, Magrini N. Audit clinico: uno strumento per favorire il cambiamento. In: Collana “Contributi per il governo clinico”. Il Pensiero Scientifico Editore Roma; 2014. (Accessed September, 2020). Available online https://assr.regione.emilia-romagna.it/pubblicazioni/collane-cessate/contributi-governo-clinico/audit_clinico

Degli Esposti L. L’equilibrio tra appropriatezza prescrittiva e sostenibilità economica: dagli indicatori di consumo agli indicatori di percorso. Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione. 6(2):5-15. (Accessed September, 2020). Available from http://www.sefap.it/web/upload/GIFF2_2014_01_DegliEsposti_ras_1.pdf

Published

2021-01-15

How to Cite

1.
Degli Esposti L, Giacomini E, Ghigi A, Perrone V. The management of patient with osteoporosis in clinical practice. abtpn [Internet]. 2021 Jan. 15 [cited 2021 Jul. 28];8(1):1-5. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2198